Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 2,871 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,871 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares in the company, valued at $1,352,700. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00.
• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Performance

Shares of NASDAQ DRTS traded up $0.05 during midday trading on Tuesday, hitting $14.75. 116,827 shares of the company’s stock were exchanged, compared to its average volume of 586,023. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.09 and a quick ratio of 7.79. The stock’s 50 day moving average price is $12.53 and its 200-day moving average price is $9.68. The firm has a market cap of $1.33 billion, a P/E ratio of -14.12 and a beta of 1.17. Alpha Tau Medical Ltd. has a twelve month low of $3.18 and a twelve month high of $15.02.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.14 million. Equities research analysts anticipate that Alpha Tau Medical Ltd. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

DRTS has been the subject of several research analyst reports. HC Wainwright upped their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Piper Sandler raised their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. LADENBURG THALM/SH SH upped their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.80.

Hedge Funds Weigh In On Alpha Tau Medical

A number of hedge funds have recently modified their holdings of the stock. Mariner LLC lifted its stake in shares of Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares during the last quarter. Millennium Management LLC increased its position in Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after buying an additional 70,081 shares during the last quarter. Renaissance Technologies LLC bought a new position in Alpha Tau Medical during the first quarter valued at about $286,000. Bank of America Corp DE lifted its position in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of Alpha Tau Medical during the 1st quarter worth about $132,000. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.